Contrasting Abliva AB (publ) (OTCMKTS:NEVPF) & Veru (NASDAQ:VERU)

Veru (NASDAQ:VERU) and Abliva AB (publ) (OTCMKTS:NEVPF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Veru and Abliva AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	-376.38%	-115.99%	-66.94%
Abliva AB (publ)	N/A	-131.68%	-113.12%

Earnings and Valuation

This table compares Veru and Abliva AB (publ)”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$14.09 million	9.68	-$93.15 million	($0.34)	-2.74
Abliva AB (publ)	$10,000.00	403.01	-$9.01 million	N/A	N/A

Abliva AB (publ) has lower revenue, but higher earnings than Veru.

Institutional and Insider Ownership

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Veru has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500. Comparatively, Abliva AB (publ) has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Veru and Abliva AB (publ), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	0	0	4	0	3.00
Abliva AB (publ)	0	0	0	0	N/A

Veru currently has a consensus target price of $4.00, indicating a potential upside of 329.05%. Given Veru’s higher possible upside, equities analysts plainly believe Veru is more favorable than Abliva AB (publ).

Summary

Veru beats Abliva AB (publ) on 7 of the 11 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Abliva AB (publ)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.